US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.

Pink Sheet Perspectives 2017 - 2018

With a historic high of second half of breakthrough therapy designation awards, the US FDA has set another yearly record of designations, with the agency granting a total of 56 in 2017.

The breakthrough therapy program – which has been a source of pride and exhaustion for the agency – completed its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet